Drugs unproven of its bio-equivalency to exit in 2007

The KFDA policy prescribes that the drug without bio-equivalency proof should gradually exit from the market through the suspension of sales or cancellation of product registration starting from 2007 for the purpose of encouraging the substituted dispensing at pharmacies.

The new provisions for the tablet, capsule, suppository and combined product registration may require its bio-equivalen...